Design Transfer to Manufacturing for Medical Devices: DMR Readiness, Process Validation, and Supplier Handoff

Why Design Transfer Is Where Most Medical Device Projects Fail

Design transfer is the controlled handoff from research and development to manufacturing. It is the moment when the verified, validated design becomes a producible product. And it is the phase where medical device companies most often encounter costly delays, compliance gaps, and rework — because the design was never created with manufacturing in mind.

The FDA's requirement for design transfer is famously brief — a single sentence in 21 CFR 820.30(h): "Each manufacturer shall establish and maintain procedures to ensure that the device design is correctly translated into production specifications." ISO 13485:2016 Clause 7.3.8 adds more detail, requiring documented procedures that verify design outputs are suitable for manufacturing before becoming final production specifications, and that production capability can meet product requirements.

Under the Quality Management System Regulation (QMSR), effective February 2, 2026, the FDA incorporates ISO 13485 by reference, and design transfer expectations are now framed through ISO 13485 Clause 7.3.8 (Design and Development Transfer). The requirement is no longer a passive milestone — it is an active, verifiable process with documented evidence of manufacturing readiness.

This guide covers the complete design transfer process: when to start, what to prepare, how to structure the DMR, how to approach process validation, and how to manage the supplier handoff.

Regulatory Requirements for Design Transfer

FDA 21 CFR 820.30(h) — Design Transfer

The legacy FDA requirement states:

Each manufacturer shall establish and maintain procedures to ensure that the device design is correctly translated into production specifications.

Despite its brevity, this sentence imposes significant obligations:

• Procedures must exist — design transfer cannot be ad hoc
• The design must be correctly translated — meaning production specifications must accurately reflect the approved design
• Production specifications must be complete — sufficient to build the device consistently

ISO 13485:2016 Clause 7.3.8 — Design and Development Transfer

ISO 13485 provides more explicit requirements:

The organization shall document procedures for transfer of design and development outputs to manufacturing. These procedures shall ensure that design and development outputs are verified as suitable for manufacturing before becoming final production specifications and that production capability can meet product requirements. Results and conclusions of the transfer shall be recorded.

This adds three specific requirements beyond the FDA text:

1. Suitability verification: Design outputs must be verified as suitable for manufacturing before becoming production specifications
2. Production capability confirmation: The manufacturing operation must be proven capable of meeting product requirements
3. Recorded results and conclusions: The transfer process must generate documented evidence

QMSR and the New Expectations

Under QMSR, terminology shifts align with ISO 13485:

The FDA confirmed in its CDRH Town Hall that it does not expect organizations to retroactively change terminology in pre-February 2026 design files, but manufacturers should conduct a gap analysis to ensure ISO 13485 requirements are met for devices marketed after the QMSR effective date.

When to Start Design Transfer

The most critical insight about design transfer is this: it is not a single event at the end of development. Design transfer activities should begin during the design process, not after design validation is complete.

The Continuous Transfer Approach

Effective design transfer happens in three overlapping phases:

Phase 1: Design for Manufacturability (During Design)

• Involve manufacturing engineers in design reviews from DR-2 onward
• Evaluate design choices against production capabilities and constraints
• Conduct Design for Manufacturing (DFM) and Design for Assembly (DFA) analyses
• Identify critical-to-quality (CTQ) dimensions and features early
• Begin supplier evaluation and qualification for custom components
• Document manufacturing considerations as part of design outputs

Phase 2: Pilot Production (During Verification/Validation)

• Build pilot units using production-equivalent processes
• Validate that assembly instructions are clear and complete
• Photograph builds in progress — cell phone photos of each assembly step save significant time when writing or updating work instructions later
• Record actual build times for each assembly step to inform cycle time planning and manufacturing cost estimates
• Document in real time — do not rely on retrospective reconstruction of build procedures
• Identify process parameters that need validation (IQ/OQ/PQ)
• Begin process validation protocols
• Test incoming inspection criteria against actual supplier parts
• Verify that test equipment and fixtures produce reliable results
• Validate test methods — confirm that inspection methods can reliably detect defects at the specified acceptance limits

Phase 3: Production Readiness (After Validation)

• Complete all process validation (IQ/OQ/PQ)
• Finalize and release the DMR/MDF
• Qualify all suppliers and establish quality agreements
• Complete production personnel training
• Conduct a formal design transfer review (DR-6)
• Release the first production batch under full DMR controls

FDA Guidance on Timing

The FDA's design control regulation states that design validation must be performed "on initial production units, lots, or batches, or their equivalents." This means the manufacturing process must be sufficiently defined to produce representative units before validation can be considered complete — reinforcing the need to begin transfer activities before the end of development.

DMR Readiness: Building the Manufacturing Specification

The Device Master Record (DMR), or Medical Device File (MDF) under ISO terminology, is the complete manufacturing specification for the device. It is the single most important deliverable of design transfer.

DMR Components and Their Design Output Sources

DMR Readiness Checklist

Before design transfer can be completed, verify the following DMR elements:

Documentation Completeness

• All drawings are at the correct revision and approved
• BOM is complete with all components, revisions, and quantities
• Assembly instructions are written, reviewed, and approved
• Test procedures with acceptance criteria are defined
• Packaging and labeling specifications are finalized
• All documents are under document control with proper versioning

Manufacturability

• Tolerances are achievable with available manufacturing equipment
• Materials are available from qualified suppliers
• Assembly sequence is logical and has been tested with pilot builds
• Cycle times are compatible with production volume requirements
• Rework and reprocessing procedures are defined where applicable

Traceability

• Every DMR specification traces to a design output
• Every design output traces to a design input
• Risk control measures from the risk management file are implemented in the DMR
• The traceability matrix is complete and current

Process Validation: IQ, OQ, PQ

Process validation is required for any manufacturing process where the result cannot be fully verified by subsequent inspection or testing. Under both FDA 21 CFR 820.75 and ISO 13485, these processes must be validated with a high degree of assurance.

Which Processes Require Validation?

Not every manufacturing process requires formal IQ/OQ/PQ validation. Validation is required when:

• Product quality cannot be verified through end-stage inspection alone
• Defects may not be detectable until the device is in use
• The process introduces variability that affects safety or performance

Common medical device processes that typically require validation:

IQ, OQ, PQ Structure

Installation Qualification (IQ)

IQ verifies that the equipment is installed correctly per the manufacturer's specifications and that all required utilities, connections, and environmental conditions are in place.

Key IQ activities:

• Verify equipment model and serial number against specifications
• Confirm utility connections (power, compressed air, water, HVAC)
• Verify calibration of instruments and gauges
• Confirm environmental conditions (temperature, humidity, cleanroom class)
• Document the installation with photographs and checklists
• Verify software versions and configurations

Operational Qualification (OQ)

OQ demonstrates that the equipment operates within its design specifications across the full range of expected operating parameters. It establishes the process window.

Key OQ activities:

• Define upper and lower operating limits for critical parameters
• Run the process at extreme parameter combinations (worst-case conditions)
• Verify that product produced at parameter limits meets specifications
• Identify the optimal operating range within the proven acceptable range
• Document all parameter settings, test results, and observations
• Perform challenge tests (e.g., deliberately introduce process upsets to verify alarms and recovery)

Performance Qualification (PQ)

PQ demonstrates that the process consistently produces product meeting specifications under routine operating conditions over an extended period.

Key PQ activities:

• Run the process at nominal (center-point) parameters for a defined number of consecutive batches (typically 3 minimum)
• Sample and test product from each batch per the sampling plan
• Verify that all acceptance criteria are met across all batches
• Demonstrate reproducibility (same results from different operators, shifts, or days)
• Document all results with statistical analysis where applicable

Validation Documentation

Each validation stage requires a protocol and a report:

• Validation Master Plan (VMP): Overarching document listing all processes requiring validation, their priority, approach, and schedule
• IQ/OQ/PQ Protocols: Pre-approved documents defining objectives, methods, acceptance criteria, and sampling plans
• IQ/OQ/PQ Reports: Post-execution documents recording results, deviations, conclusions, and approval

Process Validation Under QMSR

Starting February 2, 2026, process validation requirements are integrated into the QMSR through ISO 13485. Key changes include:

• Risk-based approach: ISO 13485 Clause 7.5.6 requires validation based on risk, with records demonstrating that processes can consistently meet requirements
• Documented evidence: The validation must produce objective evidence that the process achieves planned results
• Revalidation triggers: Processes must be revalidated when changes are made that could affect the original validation

Process validation remains one of the top FDA inspection findings, with 21 CFR 820.75 frequently cited among the top deficiencies in warning letters.

Supplier Handoff: Managing the External Supply Chain

For most medical device companies, design transfer involves not just internal manufacturing but also external suppliers and contract manufacturers. The supplier handoff is a critical and often underestimated part of design transfer.

Supplier Qualification Before Transfer

Before transferring design outputs to a supplier, the manufacturer must:

1. Qualify the supplier per ISO 13485 Clause 7.4.1 — evaluate their QMS, capabilities, and track record
2. Establish a quality agreement — a formal document defining roles, responsibilities, change notification requirements, and quality expectations
3. Verify supplier capability — confirm the supplier can meet specifications through trial runs, first article inspection, or qualification builds
4. Define incoming acceptance criteria — specify what will be inspected, how, and with what acceptance limits when receiving supplier product

What to Transfer to Suppliers

The supplier handoff package typically includes:

• Technical data package: Drawings, specifications, and BOMs for the components or assemblies the supplier will produce
• Process requirements: Specific process parameters, equipment requirements, and environmental conditions
• Acceptance criteria: What constitutes conforming product, including inspection methods and sampling plans
• Material specifications: Required materials with approved grades and suppliers
• Labeling and traceability requirements: How product must be identified and traced
• Change notification requirements: Procedural requirements for the supplier to notify the device manufacturer before making any changes
• Record retention requirements: How long and in what format supplier quality records must be maintained

Contract Manufacturer Specific Considerations

When using a contract manufacturer (CMO) for final device assembly:

• The device manufacturer retains ultimate regulatory responsibility — the CMO's quality system must be evaluated and monitored
• Quality agreements must be in place before any production begins, covering change control, complaint handling, CAPA, and record access
• Process validation may be performed by the CMO but must be reviewed and approved by the device manufacturer
• DHF/DDF access — the device manufacturer must have access to all design and development records, even if maintained at the CMO's facility
• FDA registration — the CMO must register as a contract manufacturer with the FDA and list the devices they produce

Under QMSR, the FDA's draft guidance on quality management system information for premarket submissions (October 2025) emphasizes clear identification of all manufacturing sites, including contract manufacturers, with FEI numbers and inspection-ready documentation.

Design Transfer Review (DR-6)

The final design review before production release is the design transfer review. This review confirms that all transfer activities have been completed and documented.

DR-6 Review Inputs

• Complete DMR/MDF with all components approved and released
• Process validation reports (IQ/OQ/PQ) for all validated processes
• Supplier qualification records and quality agreements
• First article inspection results
• Pilot build records demonstrating manufacturability
• Updated risk management file reflecting production risks (PFMEA)
• Production personnel training records
• Complete traceability matrix from user needs through design to production
• All previous design review action items closed

DR-6 Decision Criteria

The design transfer review should evaluate:

• Design output completeness: Are all design outputs accounted for in the DMR?
• Manufacturing process capability: Have all critical processes been validated?
• Supply chain readiness: Are all suppliers qualified and quality agreements in place?
• Documentation integrity: Is the DMR complete, approved, and under document control?
• Risk management continuity: Have production risks been assessed and mitigated?
• Training completion: Are all production personnel trained on the new processes?
• Regulatory readiness: Is the device ready for submission (if applicable)?

The decision options are:

• Transfer approved: Proceed to production
• Transfer approved with conditions: Proceed with documented conditions that must be met within a defined timeframe
• Transfer not approved: Additional work required before production can begin

Common Design Transfer Pitfalls

1. Waiting Until the End to Start

The single most common mistake is treating design transfer as a final-phase activity. When manufacturability is not considered during design, the transfer reveals problems that require design changes, which in turn require re-verification and re-validation.

Solution: Begin DFM/DFA analysis during the design output phase. Include manufacturing engineers in design reviews from DR-2 onward.

2. Incomplete DMR

Handing the manufacturing team a collection of uncontrolled documents instead of a structured, approved DMR is a recipe for inconsistency and noncompliance.

Solution: Build the DMR incrementally as design outputs are approved. Use a DMR checklist to track completeness throughout development.

3. Skipped or Inadequate Process Validation

Skipping IQ/OQ/PQ for processes that cannot be fully verified by inspection is a top FDA finding. Validation must be complete before production release.

Solution: Identify processes requiring validation during the design phase. Begin validation protocols during pilot production. Complete PQ before the design transfer review.

4. Poor Supplier Communication

Transferring design intent without adequate communication leads to suppliers producing parts that meet the drawing but not the function — because tolerances, critical features, and assembly context were not communicated.

Solution: Include functional context in supplier packages. Conduct face-to-face or video kick-off meetings for critical components. Perform first article inspection on initial production lots.

5. No Formal Transfer Procedure

Companies that lack a documented design transfer procedure cannot demonstrate compliance to auditors. The procedure is the foundation — without it, every other transfer activity lacks a governing framework.

Solution: Write and approve a design transfer SOP that defines roles, required activities, acceptance criteria, and documentation requirements. Train all relevant personnel on the procedure.

Checklist: Design Transfer Readiness

Use this comprehensive checklist before approving design transfer:

Procedures and Planning

• Design transfer procedure is established and approved
• Design plan includes transfer milestones and timing
• Transfer plan identifies all required activities, owners, and deadlines

DMR/MDF Completeness

• All device specifications are released and approved
• BOM is complete, reconciled, and matches design outputs
• Assembly instructions are written, reviewed, and tested with pilot builds
• Test procedures with acceptance criteria are defined for incoming, in-process, and final
• Packaging and labeling specifications are finalized and compliant (UDI, GUDID)
• Equipment specifications are documented and equipment is qualified

Process Validation

• All processes requiring validation are identified
• Validation Master Plan is approved
• IQ is complete for all relevant equipment
• OQ is complete with proven acceptable ranges documented
• PQ is complete demonstrating consistent production over multiple batches
• All validation reports are approved and filed

Supplier Readiness

• All suppliers are qualified per ISO 13485 Clause 7.4.1
• Quality agreements are in place with all critical suppliers and CMOs
• First article inspections are complete for all purchased components
• Incoming acceptance criteria are defined and inspection methods are validated
• Supplier change notification procedures are documented

Risk Management

• PFMEA (Process FMEA) is completed for manufacturing processes
• Risk control measures from design risk management are implemented in production
• Production risks are assessed and mitigated
• Risk management file is updated to reflect transfer activities

Training and Documentation

• Production personnel are trained on new processes (training records documented)
• All design review action items are closed
• Complete traceability matrix from user needs to production specifications
• DHF/DDF is complete and accessible
• Design transfer review (DR-6) is conducted with documented decision

Key Takeaways

Design transfer is the critical bridge between development and production for medical devices. Under FDA 21 CFR 820.30(h), ISO 13485 Clause 7.3.8, and the QMSR, it requires documented procedures, verified suitability of design outputs for manufacturing, proven production capability, and recorded results. The most successful transfers begin during the design phase with manufacturing involvement, build the DMR incrementally, validate all critical processes through IQ/OQ/PQ, and conclude with a formal transfer review that confirms readiness for production. When done right, design transfer is a verification step — not a rescue mission.